Invivyd to present data at 2024 american society of clinical oncology (asco) annual meeting and 2024 american transplant congress (atc)

Waltham, mass., may 29, 2024 (globe newswire) -- invivyd, inc. (nasdaq: ivvd), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that it will present preliminary, subset analyses from the canopy phase 3 clinical trial of vyd222 (pemivibart) for pre-exposure prophylaxis of covid-19 at the 2024 american society of clinical oncology (asco) annual meeting and at the 2024 american transplant congress (atc).
ATC Ratings Summary
ATC Quant Ranking